Tonapofylline (Synonyms: BG 9928) |
Catalog No.GC37815 |
La tonapofilina (BG 9928) es un antagonista del receptor de adenosina A1 selectivo y activo por vÍa oral con una Ki de 7,4 nM para el receptor de adenosina A1 humana (hA1), que muestra una selectividad de 915 veces frente al receptor de adenosina A2A humana y una selectividad de 12 veces frente a la adenosina A2B humana receptor y se utiliza en desarrollo para el tratamiento de la insuficiencia cardÍaca.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 340021-17-2
Sample solution is provided at 25 µL, 10mM.
Tonapofylline (BG 9928) is an orally active and selective adenosine A1 receptor antagonist with a Ki of 7.4 nM for human adenosine A1 receptor (hA1), which displays 915-fold selectivity versus human adenosine A2A receptor and 12-fold selectivity versus human adenosine A2B receptor and is used in development for the treatment of heart failure[1][2]. Ki: 7.4 nM (Human adenosine A1 receptor)[1]
Tonapofylline (BG 9928) (1 mg/kg; p.o., b.i.d, days 0-6) produces sustained reductions in post-Cisplatin serum creatinine and blood urea nitrogen levels, improves body weight recovery and significant attenuation of Cisplatin-induced (5.5 mg/kg) kidney pathology scores[3]. Animal Model: Female viral antigen-free Sprague-Dawley rats[3]
[1]. Kiesman WF, et al. Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. J Med Chem. 2006 Nov 30;49(24):7119-31. [2]. Ensor CR, et al. Tonapofylline: a selective adenosine-1 receptor antagonist for the treatment of heart failure. Expert Opin Pharmacother. 2010 Oct;11(14):2405-15. [3]. Gill A, et al. Protective effect of tonapofylline (BG9928), an adenosine A1 receptor antagonist, against cisplatin-induced acute kidney injury in rats. Am J Nephrol. 2009;30(6):521-6.
Average Rating: 5
(Based on Reviews and 6 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *